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Key summary points
Aim To summarize the prevalence of diabetes in people with sarcopenia (and vice versa) through a meta-analytic approach 
of available observational studies.
Findings In this work, we have presented the findings of the first full methodological systematic review and meta-analysis 
of observational studies exploring the relationship between diabetes and sarcopenia. Our findings overall emphasize the 
reciprocal relationship between diabetes and sarcopenia in terms of risk of occurrence, that is sarcopenia increases the risk 
of diabetes being present and vice versa.
Message This study provides support for further research into the prognosis of people with both diabetes and sarcopenia 
and the value of interventional strategies in sarcopenia to minimize adverse outcomes such as premature death, hospitaliza-
tion, and disability.
Abstract
Purpose Sarcopenia and diabetes are two common conditions in older people. Some recent literature has proposed that 
these two conditions can be associated. However, to date, no attempt has been made to collate this literature. Therefore, we 
aimed to summarize the prevalence of sarcopenia in diabetes (and vice versa) and the prevalence of sarcopenia in people 
with diabetes complications, through a systematic review and meta-analysis.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4199 9-019-00216 -x) contains 
supplementary material, which is available to authorized users.
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Methods Two authors searched major electronic databases from inception until March 2019 for case control/cross-sectional/
longitudinal studies investigating sarcopenia and diabetes. The strength of the reciprocal associations between sarcopenia 
and diabetes was assessed through odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for potential confound-
ers, where possible.
Results From 953 potential eligible articles, 20 were included in the systematic review, with 17 providing data for meta-
analysis. Overall, 54,676 participants were included (mean age = 65.4 years). Diabetic participants had an increased preva-
lence of sarcopenia compared to controls (n = 10; OR = 1.635; 95% CI 1.204–2.220; p = 0.002; I2 = 67%), whilst, after 
adjusting for potential confounders, sarcopenia was associated with an increased odds of having diabetes (OR = 2.067; 95% 
CI 1.396–3.624; p < 0.0001; I2 = 0%). In 1868 diabetic participants with a complication, there was an increased prevalence 
of sarcopenia (OR = 2.446; 95% CI 1.839–3.254; p < 0.0001; I2 = 0%), as compared with those with no complication. Very 
limited data existed regarding studies with a longitudinal design.
Conclusions Our study suggests a bidirectional association between diabetes and sarcopenia, particularly when diabetic 
complications are present.
Keywords Diabetes · Sarcopenia · Physical performance · Meta-analysis
Introduction
The prevalence of diabetes mellitus (DM) is increasing 
worldwide, particularly in older age. This is due in part to 
increased survival owing to advances in the management of 
DM and of DM comorbidity [1, 2] and in part due to increas-
ing population age and urbanisation of lifestyle [3]. During 
the last decade there has been increasing recognition of other 
diabetes-related complications such as frailty and sarcopenia 
which have become areas of new research interest [4].
Sarcopenia is the pathological loss of skeletal muscle 
mass associated with the loss of power and function [5, 6]. 
It is reported that sarcopenia affects approximately 10% of 
older people [7] and this condition, similarly to diabetes, 
is associated with several negative outcomes in older peo-
ple, including premature mortality, re-hospitalization and 
disability [8, 9]. As skeletal muscle plays a major role in 
glucose metabolism and if altered can lead to insulin resist-
ance [10], it has been postulated that sarcopenia and diabe-
tes may be associated [4]. Epidemiological studies suggest 
that diabetes is related to an accelerated decrease in physical 
performance and muscle strength parameters [11–13] and 
consequently may lead to sarcopenia, whilst conversely, sar-
copenic patients can be at an increased risk of diabetes, e.g., 
for higher sedentary behaviour prevalence [14].
Studies of sarcopenia in older people with diabetes are 
few and there is a lack of an in depth analysis of observa-
tional studies in this area [15]. Given this background, we 
aimed to summarize the prevalence of sarcopenia in diabetes 
(and vice versa) and the prevalence of sarcopenia in people 
with diabetes and macro- or micro-angiopathy complica-
tions versus those without, through a systematic review and 
meta-analysis of observational studies regarding this topic.
Methods
This systematic review adhered to the PRISMA [16] and 
MOOSE [17] statements and followed a structured, but 
unpublished protocol.
Data sources and literature search strategy
Two investigators (NV and DP) independently conducted 
a literature search using PubMed, EMBASE, SCOPUS, 
Cochrane Central Register of Controlled Trials and Clini-
caltrials.gov without language restriction, from database 
inception until 01st March 2019 for observational studies 
investigating the prevalence of sarcopenia in participants 
with diabetes (vs. those without) and vice versa. Moreo-
ver, we included studies assessing the prevalence of sarco-
penia in participants with diabetes and its usual macro- or 
micro-angiopathy complications vs. people with diabetes but 
without complications. Any inconsistencies were resolved 
by consensus with a third author (SM).
In PubMed, the following search strategy was used: “dia-
betes [tiab] AND sarcopenia [tiab]”. Conference abstracts 
and reference lists of included articles were hand-searched 
to identify any potential additional relevant articles.
Study selection
Inclusion criteria for this meta-analysis were: (1) diagnosis 
of diabetes (e.g., self-reported, according to the American 
Diabetes Association criteria [18]) not limited only to type 
2; (2) diagnosis of sarcopenia: in this case we included 
standardized methods of determining sarcopenia (e.g., Asia 
Working Group for Sarcopenia, AWGS [19] or European 
Working Group on Sarcopenia in Older People, EWGSOP 
[5] criteria) or diagnosis through body composition or 
muscle mass/physical performance parameters, according 
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to validated criteria. Studies were excluded if: (1) did not 
include humans; (2) did not report any meta-analysable data.
Data extraction
Two independent investigators (NV and DP) extracted key data 
from the included articles in a standardized Excel sheet. A third 
independent investigator (SM) checked the extracted data. For 
each article, we extracted data on authors, year of publication, 
country, setting, condition, number of participants, demograph-
ics (mean age, mean body mass index, BMI), diagnostic crite-
ria for diabetes and sarcopenia, main findings for each paper, 
number and type of covariates used in multivariable analysis.
Outcomes
The primary outcomes considered were the prevalence of sar-
copenia in diabetes and vice versa and the prevalence of sarco-
penia in people with diabetes and macro- or micro-angiopathy 
complications (vs. those without). The data should be reported 
as number of events or as adjusted odds ratios (ORs).
Assessment of study quality
The Newcastle–Ottawa Scale (NOS) [20, 21] was used to 
assess study quality. The NOS assigns a maximum of nine 
points based on three quality parameters: selection, com-
parability, and outcome, with a cut-off of ≤ 5 being indica-
tive of high risk of bias. NOS scores were assessed by two 
investigators (DP, NV) and a consensus was reached in case 
of discrepancy [20, 21].
Data synthesis and statistical analysis
All analyses were performed using Comprehensive Meta-
Analysis (CMA) three. Only outcomes having at least three 
studies were meta-analysed; the other outcomes were sum-
marized descriptively.
The primary analysis compared the prevalence of sar-
copenia in diabetes and vice versa and the prevalence of 
sarcopenia in people with diabetes and macro- or micro-
angiopathy complications (vs. those without), applying a 
random-effect model [22]. The data were reported as ORs 
with their 95% confidence intervals (CIs).
Heterogeneity across studies was assessed by the I2 
metric. Given significant heterogeneity (I2 > 50% and/or 
p < 0.05) [23] and having at least 10 studies for each out-
come, meta-regression analyses were carried out, taking as 
moderators the following factors: mean age and the differ-
ence in mean age between diabetic and controls, NOS score, 
the diagnostic criteria of diabetes or sarcopenia.
Publication bias was assessed by a visual inspection of 
funnel plots and calculating the Egger bias test [24]. We also 
reported the fail-safe number (i.e., the number of studies 
bringing alpha over the p value) and trim and fill analyses 
were performed [25].
For all analyses, a p value less than 0.05 was considered 
statistically significant.
Results
Search results
As shown in eFig. 1, altogether, the searches gave 953 non-
duplicated articles. After excluding 920 articles based on 
title/abstract review, 33 articles were retrieved for full text 
review. Among these, 20 studies were included in the sys-
tematic review [26–45] and 17 of them in the meta-analysis: 
two studies, in fact, were longitudinal [41, 42] and another 
one adjusted estimates for the association between diabetic 
complications and sarcopenia, without reporting the preva-
lence of sarcopenia in those having diabetes complications 
[26].
Study and patient characteristics
Table 1 summarizes the data regarding the included stud-
ies. Overall, 54,676 participants were included having a 
mean age of 65.4 years (SD = 11.2), with a mean BMI of 25 
(SD = 3.7). Of the 20 studies included, the majority (n = 14) 
were carried out in Asia. Seven studies investigated par-
ticipants having type two diabetes and six studies used the 
criteria suggested by the AWGS that defined sarcopenia as 
low skeletal muscle mass plus low muscle strength and/or 
low physical performance according to predefined criteria 
[19]. All the studies used diagnosis of diabetes validated by 
a physician or using medical data.
Looking to the main findings of the included articles, we 
observed a significant association between diabetes and sar-
copenia and vice versa.
The median NOS was 6 (range 3–8), indicating a suf-
ficient quality of the studies included.
Prevalence of sarcopenia in diabetes
Figure 1 reports the prevalence of sarcopenia in participants 
with diabetes versus controls. In patients with diabetes, the 
prevalence of sarcopenia was 28.4% (95%CI 18.9–40.2), 
whilst in the control group was 18.7% (95%CI 11.9–28.1). 
Ten studies were included, overall showing that diabetic par-
ticipants had an increased prevalence of sarcopenia com-
pared to controls (n = 10; OR = 1.635; 95% CI 1.204–2.220; 
p = 0.002; I2 = 67%). The meta-regression analysis (using 
as moderators mean age and the difference in mean age 
between diabetic and controls, NOS score, the diagnostic 
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criteria of diabetes or sarcopenia) did not explain any of the 
heterogeneity found (details available upon request).
The Egger’s test suggested that there was a potential 
publication bias (= 1.88 ± 0.85; p = 0.05). The trim and fill 
analysis suggested that, after trimming two studies at the 
left of the mean, the recalculated OR was 1.478 (95% CI 
1.080–2.026). The fail-safe number for this outcome was 
63. Only one study reported data adjusted for potential con-
founders, substantially confirming these findings [45].
Association between sarcopenia and diabetes
Figure 2 reports the association between sarcopenia and 
diabetes, adjusted for potential confounders. This analysis 
involved 37,396 participants. After adjusting for a median 
of three potential covariates (range 0–7), sarcopenia was 
associated with an increased odds of having diabetes 
(OR = 2.067; 95% CI 1.396–3.624; p < 0.0001; I2 = 0%). 
This outcome did not suffer on publication bias as revealed 
by the visual inspection of the funnel plots and/or using the 
Egger’s test (p value > 0.05). The fail-safe number was nine.
One study reported the association between sarcopenia at 
baseline (reported as the lowest tertile of handgrip strength 
at the baseline) and incident diabetes in the English Lon-
gitudinal Study of Ageing [41]. After adjusting for seven 
potential confounders, in more than 5000 participants, the 
authors failed to find any significant association between 
these two conditions.
Fig. 1  Odds ratio of sarcopenia in diabetic participants vs. healthy controls
Fig. 2  Adjusted odds ratio of diabetes in sarcopenia vs. healthy controls
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Association between diabetes complications 
and sarcopenia
As reported in Fig. 3, five studies reported the associa-
tion between diabetes complications and the presence of 
sarcopenia. Retinopathy was the most common complica-
tion assessed. These studies included 1868 participants 
and reported that diabetic people with a complication had 
an increased prevalence of sarcopenia when compared to 
diabetic people without (OR = 2.446; 95%CI 1.839–3.254; 
p < 0.0001; I2 = 0%). This outcome did not suffer on publica-
tion bias as revealed by the visual inspection of the funnel 
plots and/or using the Egger’s test (p value > 0.05). The fail-
safe number was 36.
One cross-sectional study confirmed these findings, 
using an OR adjusted for 11 potential confounders [26]. 
Interestingly, one study reported the prospective association 
between sarcopenia at baseline and incident micro-albumi-
nuria, again supporting the potential association between 
sarcopenia and poor renal function [42].
Discussion
In this systematic review and meta-analysis which included 
20 studies, we found that sarcopenia was more prevalent 
in diabetic patients (when compared to their counterparts 
without diabetes) and associated with an increased odds of 
having diabetes in 37,396 participants. Moreover, diabetic 
complications were associated with a higher frequency of 
sarcopenia, when compared to people with diabetes, but 
without any complication. In that sense, one longitudi-
nal study suggests that sarcopenia can be associated with 
a decline in renal function. Taken together, these findings 
suggest a bidirectional association between diabetes and 
sarcopenia and that the presence of a diabetic complication 
can further increase the presence of sarcopenia.
The association between insulin resistance (as observed 
in type 2 diabetes), abdominal obesity and sarcopenia may 
be explained by several pathways, such as the loss of the 
anabolic action to insulin, the reduced insulin-inhibition 
of proteolysis, and the loss of anti-inflammation actions. 
Inflammation (particularly when associated with obesity) 
is an important determinant of sarcopenia, as we recently 
reported in a systematic review and meta-analysis regard-
ing this topic [46]. For example, TNF-α, which is highly 
expressed in adipose tissues in obese subjects may block 
muscle tissues differentiation leading to sarcopenia [47]. 
Other works have reported that a reduction in oxidative 
type I fibres and a concomitant increase in glycolytic type 
IIb fibres, combined with ageing effects on muscle, leads 
to an overall decrease in mitochondrial function and conse-
quently an increase in insulin resistance and oxidative stress, 
finally leading to sarcopenia [4, 47]. Finally, insulin resist-
ance may also alter the glycogen storage in type IIa muscle 
fibres, decreasing the efficiency of oxidative phosphorylation 
[48]. In this sense, a study excluded from our meta-analysis 
since the cohort was already included (Korean Sarcopenic 
Obesity Study) and no meta-analysable data were available, 
reported that appendicular skeletal mass values were sig-
nificantly decreased in patients with diabetes compared with 
subjects without diabetes [49].
From an epidemiological point of view, sarcopenia and 
diabetes seem to be reciprocally related and could share 
similar pathogenetic pathways. As diabetes leads to sarco-
penia, as mentioned before, it is also possible that sarcopenia 
can lead to lower muscle glucose uptake, hyperglycaemia/
hyperinsulinemia and finally to insulin resistance, precur-
sors of diabetes [50]. We have also reported that poor physi-
cal performance can be associated with an increased risk 
of diabetes [51]. Muscle fat infiltration, a component that 
Fig. 3  Odds ratio of sarcopenia in diabetic people with micro or macro-complications vs. diabetics without complications
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seems increasingly important in several aspects of geriat-
ric medicine, might also lead to insulin resistance promot-
ing both the development of sarcopenia and diabetes [51]. 
On the contrary, in the only study including people with 
latent autoimmune diabetes of adults, we did not observe 
any significant difference in sarcopenia prevalence when 
compared to controls; overall suggesting that particularly 
insulin-resistance typical of type 2 diabetes is implicated 
in the development of sarcopenia [38]. Chronic low-grade 
inflammation is another factor that can have a role in the 
development of both diabetes and sarcopenia [46, 52, 53].
Finally, we found that sarcopenia is more common in dia-
betic people with complications than in DM patients without 
complications. Even if this analysis is limited by the fact 
that all the complications were pooled together (micro and 
macro-vascular), these findings suggest a potential role of 
the vascular system in the development of sarcopenia [54]. 
In one exploratory study, for example, the authors found 
that in sarcopenic patients there was a lower skeletal muscle 
capillarization that may contribute to the development of 
sarcopenia and reduced exercise capacity by limiting the 
diffusion of substrates essential for the muscle, such as oxy-
gen, hormones, or nutrients [55]. However, it is also possible 
that the complication profile depends on the mechanisms of 
diabetes itself and that the contribution of vascular factors, 
even if pivotal, is probably not enough to explain the link 
that we observed.
Our meta-analysis reports, however, some preliminary 
findings regarding the potential association between sarco-
penia and diabetes and vice versa limited to cross-sectional 
and case–control studies. We can suggest that future longi-
tudinal studies could specifically investigate, for example, 
the role of singular complication in predicting sarcopenia 
(e.g., neuropathy or renal failure) or the role of sarcopenia 
in predicting more rare forms of diabetes such as type 1 
diabetes and LADA.
Findings from the present meta-analysis should be inter-
preted within its limitations. First, the results were heter-
ogenous. Second, our findings were mainly based on case 
control or cross-sectional studies, whilst only two papers 
were longitudinal. Moreover, in case control and cross-sec-
tional studies, the prevalence of sarcopenia in diabetes is not 
adjusted for potential confounders. Third, the diagnosis of 
sarcopenia was made through multidimensional tools only 
in 8 over 20 studies, whilst many others assessed sarcopenia 
only through muscle mass or muscle function parameters. 
Fourth, the majority of the studies included Asiatic peo-
ple and the mean age was only 65 years, suggesting that 
further studies in more old people are needed. Finally, in 
the outcome characterized by a high heterogeneity (i.e., the 
prevalence of sarcopenia in diabetes), we were not able to 
find any significant moderator explaining this factor. In this 
regard, for example, it is possible that the higher presence 
of diabetic complications in people with diabetes than con-
trols can contribute to explain the heterogeneity found in our 
analysis. For example, some authors suggest that neuropathy 
(a common and traditional complication of diabetes) can 
lead to sarcopenia [56].
In conclusion, our systematic review and meta-analysis 
indicated that sarcopenia and diabetes can be bi-directionally 
associated, even if the findings are mainly based on cross-
sectional and case control studies. People with diabetic 
complications reported a significantly higher presence of 
sarcopenia compared to diabetic participants without com-
plications. Since both diabetes and sarcopenia are two highly 
prevalent conditions in ageing populations, future longitu-
dinal studies are needed to better explain this association.
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